Albert Einstein College of Medicine

Albert Einstein College of Medicine, founded in 1953 in the Bronx, New York, is a premier institution with excellence in graduate medical education, scientific research, and patient-centered clinical care. Established with a mission to prepare knowledgeable, compassionate physicians and innovative scientific investigators, it was named after the renowned physicist Professor Albert Einstein, who granted the institution the use of his name to support its policy of acceptance and inclusivity.

Albert Einstein College of Medicine strongly emphasizes bench-to-bedside research, facilitating discoveries in the laboratories that lead to therapies and treatments for patients. With continued support from the federal government, Albert Einstein College of Medicine received more than $192 million in funding from the National Institutes of Health (NIH) in 2023. It has over 2000 full-time faculty, 20 research centers, 36 global initiatives, and over 300 research laboratories. It offers one of the largest medical education programs in the US, with 737 MD students, 209 PhD students, and 239 postdoctoral research fellows in 2023-24. Einstein offers 7 educational programs, including MD, PhD, MD/PhD, MS, and MD/MPH. Einstein was one of the first major medical schools to integrate classroom learning with clinical experience for first-year medical students. In collaboration with Montefiore Medical Center, Einstein runs four Centers of Excellence for pediatrics, cancer care, cardiovascular care, and transplantation. Montefiore Medical Center comprises 11 hospitals and 200 outpatient care sites over a large geographic area, delivering coordinated, compassionate, and patient-centered clinical care.

Albert Einstein College of Medicine is internationally recognized as a leader in the study of diabetes and metabolism. Einstein’s joint project with Icahn School of Medicine at Mount Sinai - The Einstein-Mount Sinai Diabetes Research Center (ES-DRC) is one of the leading research centers that conducts basic, translational, behavioral, and clinical research into type 1 and type diabetes with a focus on equity. This joint research program provides leadership and infrastructure to conduct NIH-funded basic research and clinical trials, with patient-oriented research focused on minority and other underserved populations in New York City. In addition to the NIH, ES-DRC collaborates with diabetes investigators from New York University, Weill Cornell Medical College, Cornell University, New York Medical College, Winthrop University Hospital, Stony Brook University, and Hunter College. ES-DRC comprises more than 100 independent laboratories that serve as a resource center for diabetes researchers throughout the US. The landmark Diabetes Control and Complications Trial and the Diabetes Prevention Program have been instrumental in advancing the Center’s goal of preventing and managing diabetes. In April 2024, Einstein researchers published an article in Diabetes Careon the results of the multicenter GRADE study (Glycemia Reduction Approaches in Diabetes: A Comparative Effectiveness Study) examining the association of emotional distress with treatment outcomes and adherence.

Einstein’s Global Diabetes Institute (GDI) was founded in 2008 by Professor Meredith Hawkins to combat the global diabetes epidemic, especially among people with low BMI (<18.5 kg/m2). GDI aims to harness Einstein’s strengths in research, medical education, and global health to develop global partnerships for understanding the unique diabetes phenotype reported worldwide in lean people with diabetes. Through extensive research and international collaboration with its partner institutes, GDI strives to advocate recognizing this form of diabetes as a distinct type to modify its diagnosis and management approaches. In partnership with Christian Medical College, Vellore, GDI has conducted research using highly sophisticated hormone infusion clamp studies to investigate this form of diabetes. Prof. Meredith Hawkins, Prof. Nihal Thomas, and their team members have presented their study findings in several international meetings and published their research in Diabetes Care in 2022. In addition to research, GDI supports Einstein students to visit its partner institutes in India and Uganda as exchange students to educate health providers on diabetes management in resource-poor settings. During these visits, the students successfully developed a special curriculum to educate the providers and learned about practicing medicine in different clinical settings.

Albert Einstein College of Medicine received Health Professions Higher Education Excellence in Diversity Award in 2023 for its outstanding commitment to diversity and inclusion – for the third year in a row. Through innovative research, comprehensive medical education, and patient-centered clinical care, the Albert Einstein College of Medicine continues to translate scientific discoveries into therapies, deliver equitable healthcare, and educate future healthcare leaders.